Literature DB >> 17004125

Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.

Smita A Kshirsagar1, Terrence F Blaschke, Lewis B Sheiner, M Krygowski, Edward P Acosta, Davide Verotta.   

Abstract

Data from clinical trials present numerous problems for the data analyst. These include non-compliance with the prescribed dosing regimen and inaccurate recollection of dosing history by patients as well as mistakes in recording data. Several methods have been proposed to address these issues. One such technique by Lu et al. (Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J. Pharmacokinet. Pharmacodyn. 28:343-362 (2001)) identifies occasions in pharmacokinetic (PK) data where the preceding dosing history is likely to be unreliable. We used this method, implemented in the software program NONMEM (beta) VI, to clean a dataset containing indinavir (IDV) plasma concentrations from HIV-1 infected patients. The data was also cleaned by inspection in Microsoft Excel using clinical PK criteria. A one-compartment model with first order absorption and elimination was fit to both sets of cleaned data. IDV population PK parameters obtained from these analyses were similar to those reported previously. It is established that IDV nephrotoxicity is related to high IDV exposure. However, no relationships were found between any PK parameters and nephrotoxicity in the "compliance cleaned" dataset. In the "PK cleaned" dataset, the oral clearance and apparent volume were lower by 9.1% and 6.6%, respectively in patients with any type of nephrotoxicity and the maximum IDV concentration (C(max)) was 12.1% higher. In patients suffering from nephrolithiasis in particular, C(max) was 15.5% higher. Accordingly, the use of the non-compliance detection method did not improve the reliability of our dataset over the usual method of applying clinical criteria. In fact, analyses on the compliance-cleaned dataset missed some exposure-toxicity relationships. Thus, automated methods must be tested rigorously with 'real life' datasets, used with caution, and always in conjunction with clinical reasoning to avoid overlooking a signal in noisy data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004125     DOI: 10.1007/s10928-006-9032-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  45 in total

1.  Population one-compartment pharmacokinetic analysis with missing dosage data.

Authors:  Dolors Soy; Stuart L Beal; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

2.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

3.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Authors:  J P Dieleman; I C Gyssens; M E van der Ende; S de Marie; D M Burger
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

4.  Influence of environmental temperature on incidence of indinavir-related nephrolithiasis.

Authors:  E Martínez; M Leguizamón; J Mallolas; J M Miró; J M Gatell
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

5.  Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Authors:  J Lu; J M Gries; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

6.  Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.

Authors:  Jeanne P Dieleman; Annemarie M C van Rossum; Bruno C H Stricker; Miriam C J M Sturkenboom; Ronald de Groot; Denise Telgt; Willem L Blok; David M Burger; Bert G Blijenberg; Robert Zietse; Inge C Gyssens
Journal:  J Acquir Immune Defic Syndr       Date:  2003-02-01       Impact factor: 3.731

7.  Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

Authors:  Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

9.  Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

Authors:  Marc Pfister; Line Labbé; Jian-Feng Lu; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2002-08       Impact factor: 6.875

10.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

View more
  3 in total

1.  The role of Shox2 in SAN development and function.

Authors:  Hongbing Liu; Ramón A Espinoza-Lewis; Chaohui Chen; Xuefeng Hu; Yanding Zhang; Yiping Chen
Journal:  Pediatr Cardiol       Date:  2012-02-04       Impact factor: 1.655

2.  Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Authors:  Emilie Hénin; Michel Tod; Véronique Trillet-Lenoir; Catherine Rioufol; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.

Authors:  Anna H-X P Chan Kwong; Elisa A M Calvier; David Fabre; Florence Gattacceca; Sonia Khier
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-06-13       Impact factor: 2.745

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.